ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer.
|Articles|August 11, 2011
- ONCOLOGY Vol 25 No 9
- Volume 25
- Issue 9
Supplemental Figures for "Cancer and Healthcare Reform: Making the Pieces Fit"
Author(s)Thomas Main, MBA, Andrew Chadwick-jones, MA
Advertisement
Note:These supplemental figures provide concrete illustrations of a
Articles in this issue
about 15 years ago
Management of DCIS-A Work in Progressabout 15 years ago
Tailored Strategies for DCIS Managementabout 15 years ago
Neuroendocrine Tumors: a Heterogeneous Set of Neoplasmsabout 15 years ago
Can We Know What to Do When DCIS Is Diagnosed?about 15 years ago
A Rare Case of Metastatic Renal Epithelioid Angiomyolipomaabout 15 years ago
The Changing Field of Locoregional Treatment for Breast Cancerabout 15 years ago
Cancer and Healthcare Reform: Making the Pieces Fitabout 15 years ago
An Approach to the Management of Rare TumorsAdvertisement
Related to this article
Although shortages periodically capture national attention when widely used agents such as cisplatin or carboplatin become scarce, the problem extends well beyond any single drug.
Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5